Literature DB >> 18790736

MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer.

Jian-Jun Zhao1, Jianhong Lin, Hua Yang, William Kong, Lili He, Xu Ma, Domenico Coppola, Jin Q Cheng.   

Abstract

A search for regulators of estrogen receptor alpha (ERalpha) expression has yielded a set of microRNAs (miRNAs) for which expression is specifically elevated in ERalpha-negative breast cancer. Here we show distinct expression of a panel of miRNAs between ERalpha-positive and ERalpha-negative breast cancer cell lines and primary tumors. Of the elevated miRNAs in ERalpha-negative cells, miR-221 and miR-222 directly interact with the 3'-untranslated region of ERalpha. Ectopic expression of miR-221 and miR-222 in MCF-7 and T47D cells resulted in a decrease in expression of ERalpha protein but not mRNA, whereas knockdown of miR-221 and miR-222 partially restored ERalpha in ERalpha protein-negative/mRNA-positive cells. Notably, miR-221- and/or miR-222-transfected MCF-7 and T47D cells became resistant to tamoxifen compared with vector-treated cells. Furthermore, knockdown of miR-221 and/or miR-222 sensitized MDA-MB-468 cells to tamoxifen-induced cell growth arrest and apoptosis. These findings indicate that miR-221 and miR-222 play a significant role in the regulation of ERalpha expression at the protein level and could be potential targets for restoring ERalpha expression and responding to antiestrogen therapy in a subset of breast cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790736      PMCID: PMC2576549          DOI: 10.1074/jbc.M806041200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  microRNAs: tiny regulators with great potential.

Authors:  V Ambros
Journal:  Cell       Date:  2001-12-28       Impact factor: 41.582

2.  Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells.

Authors:  Peter D Adams; Paul Cairns
Journal:  Cancer Biol Ther       Date:  2003 Sep-Oct       Impact factor: 4.742

3.  Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer.

Authors:  R Cullen; T M Maguire; E W McDermott; A D Hill; N J O'Higgins; M J Duffy
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

4.  Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.

Authors:  M Sun; J E Paciga; R I Feldman; Z Yuan ; D Coppola; Y Y Lu; S A Shelley; S V Nicosia; J Q Cheng
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

5.  Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA.

Authors:  A E Pasquinelli; B J Reinhart; F Slack; M Q Martindale; M I Kuroda; B Maller; D C Hayward; E E Ball; B Degnan; P Müller; J Spring; A Srinivasan; M Fishman; J Finnerty; J Corbo; M Levine; P Leahy; E Davidson; G Ruvkun
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

6.  Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

Authors:  X Yang; D L Phillips; A T Ferguson; W G Nelson; J G Herman; N E Davidson
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

7.  The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines.

Authors:  Brian D Adams; Henry Furneaux; Bruce A White
Journal:  Mol Endocrinol       Date:  2007-02-20

8.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.

Authors:  R C Lee; R L Feinbaum; V Ambros
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

9.  The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms.

Authors:  Federica Felicetti; M Cristina Errico; Lisabianca Bottero; Patrizia Segnalini; Antonella Stoppacciaro; Mauro Biffoni; Nadia Felli; Gianfranco Mattia; Marina Petrini; Mario P Colombo; Cesare Peschle; Alessandra Carè
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

10.  Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines.

Authors:  Lan Yan; Sharyl J Nass; Dawn Smith; William G Nelson; James G Herman; Nancy E Davidson
Journal:  Cancer Biol Ther       Date:  2003 Sep-Oct       Impact factor: 4.742

View more
  244 in total

Review 1.  Micro-RNAs and breast cancer.

Authors:  John Le Quesne; Carlos Caldas
Journal:  Mol Oncol       Date:  2010-04-28       Impact factor: 6.603

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 3.  Emerging role of microRNAs in drug-resistant breast cancer.

Authors:  Sarmila Majumder; Samson T Jacob
Journal:  Gene Expr       Date:  2011

4.  A crossroad of microRNAs and immediate early genes (IEGs) encoding oncogenic transcription factors in breast cancer.

Authors:  Aldema Sas-Chen; Roi Avraham; Yosef Yarden
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-02-12       Impact factor: 2.673

Review 5.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

Review 6.  microRNAs and EMT in mammary cells and breast cancer.

Authors:  Josephine A Wright; Jennifer K Richer; Gregory J Goodall
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-25       Impact factor: 2.673

7.  Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells.

Authors:  Tissa T Manavalan; Yun Teng; Savitri N Appana; Susmita Datta; Theodore S Kalbfleisch; Yong Li; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2011-09-10       Impact factor: 8.679

Review 8.  Causes and consequences of microRNA dysregulation.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 9.  Estrogen receptors and human disease: an update.

Authors:  Katherine A Burns; Kenneth S Korach
Journal:  Arch Toxicol       Date:  2012-05-31       Impact factor: 5.153

Review 10.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.